The group is currently focusing on identifying new ovarian and breast cancer susceptibility genes through massive sequencing (sets of exomes and genes) and genome-wide association studies. The functional characterisation and expression of variants of unknown clinical importance in genes that predispose to cancer. As well as identifying BRCA mRNA isoforms as a possible new mechanism of resistance against PARP inhibitors, and the study of microRNAs and long non-coding RNAs in the susceptibility to clinical toxicity induced by radiotherapy.
It is taking part in the European REQUITE project with prospective cohorts of cancer patients treated with radiotherapy for the biomarker trials on the side effects of radiotherapy.
From 10:00 to 17:30 h.
From 9.00 am to 2.30 pm....